Literature DB >> 3862904

Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors.

K J Weinhold, D P Bolognesi, T J Matthews.   

Abstract

The antibody-dependent lytic activity of Corynebacterium parvum-induced peritoneal exudate cells was examined in vitro by utilizing AD755a tumor targets and a homologous anti-AD755a hyperimmune serum. Maximum antibody-dependent cell-mediated cytolysis (ADCC) of tumor targets was achieved within 4 hours of incubation. ADCC activity was found primarily in the plastic nonadherent cell population and was greatly enriched following removal of phagocytic cells by carbonyl iron. Phenotypically, the cells active in short-term ADCC were Qa-5+, ASGM-1+, Thy 1.2+, and NK 1.1+ and were unaffected by treatment with Lyt 1.2, Lyt 2.2, MAC-1, or I-Ab antibodies plus complement. Cells active in antibody-independent lysis of AD755a targets were phenotypically identical to antibody-dependent effectors. Although indicative of a natural killer (NK) cell phenotype, C. parvum-induced effectors differed from "spontaneous" splenic NK cells in their relative sensitivity to anti-Thy 1.2 as well as to anti-NK 1.1 treatment. Unlike the IgG2a-dependent lysis of AD755a-derived cells by inflammatory macrophages, all IgG isotypes of antiAD755a serum were equally effective in ADCC mediated by C. parvum NK cells. Finally, treatment of C. parvum-inoculated animals with anti-ASGM-1 serum eliminated in vitro NK activity and abrogated the in vivo therapeutic effects of hyperimmune serum. These findings, together with other correlations detailed herein, strongly suggested that C. parvum-activated NK cells appeared to represent a unique subset of NK cells that can serve as potent effectors in the antibody-dependent killing of AD755a tumor cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3862904

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack.

Authors:  H K Lyerly; T J Matthews; A J Langlois; D P Bolognesi; K J Weinhold
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

2.  Effect of intracerebrally injected Corynebacterium parvum on implanted brain tumor in mice.

Authors:  J D Kennedy; F K Conley
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

3.  Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.

Authors:  M Awwad; P G Strome; S C Gilman; H R Axelrod
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

4.  Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children.

Authors:  K Broliden; E Sievers; P A Tovo; V Moschese; G Scarlatti; P A Broliden; C Fundaro; P Rossi
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

5.  Antibody-dependent cellular cytotoxicity detects type- and strain-specific antigens among human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates.

Authors:  K Ljunggren; G Biberfeld; M Jondal; E M Fenyö
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

6.  Natural and antibody-dependent cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection.

Authors:  K Ljunggren; A Karlson; E M Fenyö; M Jondal
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

7.  Monoclonal anti-P-glycoprotein antibody-dependent killing of multidrug-resistant tumor cells by human mononuclear cells.

Authors:  Y Heike; H Hamada; N Inamura; S Sone; T Ogura; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1990-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.